amantadine has been researched along with Movement Disorders in 68 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An aim of a study was to establish the relationship between pain, motor complications and depression in Parkinson's disease and evaluate an effect of the 3 months therapy with the dopamine receptor agonist pramipexole (mirapex)." | 9.13 | [Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexole]. ( Letvinenko, IV; Mogil'naia, VI; Odinak, MM, 2008) |
| "Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months." | 7.65 | Treatment of involuntary movement disorders with tetrabenazine. ( Heathfield, KW; Roberts, AH; Swash, M; Zakko, H, 1972) |
| "An aim of a study was to establish the relationship between pain, motor complications and depression in Parkinson's disease and evaluate an effect of the 3 months therapy with the dopamine receptor agonist pramipexole (mirapex)." | 5.13 | [Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexole]. ( Letvinenko, IV; Mogil'naia, VI; Odinak, MM, 2008) |
| " Case 1 is a description of the subjective experience of a patient with acute orofacial dystonia from promethazine." | 3.66 | Case vignettes of movement disorders. ( Yung, CY, 1983) |
| "We have studied the urinary excretion of 1,4-methylhistamine (1,4-MeHm), 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in patients with Parkinson's disease, choreiform movements and essential tremor." | 3.65 | Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. ( Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ, 1977) |
| "Seventeen patients with choreiform, athetoid, or ballistic involuntary movements, or with spasmodic torticollis, were treated with tetrabenazine in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months." | 3.65 | Treatment of involuntary movement disorders with tetrabenazine. ( Heathfield, KW; Roberts, AH; Swash, M; Zakko, H, 1972) |
| "Amantadine is a well-tolerated and effective treatment for motor symptoms in ataxia telangiectasia." | 2.78 | Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. ( Ben-Zeev, B; Hassin-Baer, S; Lerman, SF; Levi, YB; Nissenkorn, A; Tzadok, M, 2013) |
| "Bromocriptine appears to be an interesting development in the treatment of Parkinson's disease." | 2.64 | [Treatment of parkinsonian syndromes by bromocriptin]. ( Durand, JP; Gautier, JC, 1977) |
| "Pergolide was increased to 8." | 1.33 | High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. ( Hundemer, HP; Oehlwein, C; Polzer, U; Schwarz, J; Storch, A; Trenkwalder, C; Winkelmann, J, 2005) |
| "In animal models of Parkinson's disease (PD), glutamate antagonists diminish levodopa (LD)-associated motor fluctuations and dyskinesias." | 1.30 | Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. ( Blanchet, PJ; Chase, TN; Del Dotto, P; van den Munckhof, P; Verhagen Metman, L, 1998) |
| " Memory scores were correlated with age, sex, education, marital status, length of illness, age at onset of illness, dosage and time on medication, functional status, and the major symptoms of parkinsonism." | 1.28 | Correlates of memory in Parkinson's disease. ( Reynolds, CM; Riklan, M; Stellar, S, 1989) |
| "Twenty patients with idiopathic Parkinson's disease (PD) and motor fluctuations received open-label amantadine (100-200 mg/d) in addition to their other antiparkinson medications." | 1.27 | Amantadine and motor fluctuations in chronic Parkinson's disease. ( Carroll, VS; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM, 1987) |
| " Side effects (hallucinations, confusion, dyskinesias) were frequent, but were usually reversible by lowering the dosage of levodopa or the accompanying anticholinergic medication." | 1.26 | Piribedil: its synergistic effect in multidrug regimens for parkinsonism. ( Feigenson, JS; McDowell, FH; Sweet, RD, 1976) |
| " In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly." | 1.25 | Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975) |
| " Although directly related to daily dosage of levodopa, the myoclonus was specifically blocked by the serotonin antagonist, methysergide." | 1.25 | Levodopa-induced myoclonus. ( Bergen, D; Goetz, C; Klawans, HL, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 55 (80.88) | 18.7374 |
| 1990's | 3 (4.41) | 18.2507 |
| 2000's | 5 (7.35) | 29.6817 |
| 2010's | 5 (7.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horváth, K | 1 |
| Aschermann, Z | 1 |
| Komoly, S | 1 |
| Kovács, A | 1 |
| Kovács, N | 1 |
| Lerner, PP | 1 |
| Miodownik, C | 1 |
| Lerner, V | 1 |
| Dubow, JS | 1 |
| Rezak, M | 1 |
| Berman, AA | 1 |
| Letvinenko, IV | 1 |
| Odinak, MM | 1 |
| Mogil'naia, VI | 1 |
| Stacy, M | 1 |
| Howland, RH | 1 |
| Nissenkorn, A | 1 |
| Hassin-Baer, S | 1 |
| Lerman, SF | 1 |
| Levi, YB | 1 |
| Tzadok, M | 1 |
| Ben-Zeev, B | 1 |
| Regragui, W | 1 |
| Lachhab, L | 1 |
| Razine, R | 1 |
| Benjelloun, H | 1 |
| Ait Benhaddou, EH | 1 |
| Benomar, A | 1 |
| Yahyaoui, M | 1 |
| Storch, A | 1 |
| Trenkwalder, C | 1 |
| Oehlwein, C | 1 |
| Winkelmann, J | 1 |
| Polzer, U | 1 |
| Hundemer, HP | 1 |
| Schwarz, J | 1 |
| Yung, CY | 1 |
| Schneider, E | 1 |
| Fischer, PA | 1 |
| Clemens, R | 1 |
| Balzereit, F | 1 |
| Fünfgeld, EW | 1 |
| Haase, HJ | 1 |
| König, P | 1 |
| Chwatal, K | 1 |
| Havelec, L | 1 |
| Riedl, F | 1 |
| Schubert, H | 1 |
| Schultes, H | 1 |
| Verhagen Metman, L | 1 |
| Del Dotto, P | 1 |
| Blanchet, PJ | 1 |
| van den Munckhof, P | 1 |
| Chase, TN | 1 |
| Růzicka, E | 1 |
| Streitová, H | 1 |
| Jech, R | 1 |
| Kanovský, P | 1 |
| Roth, J | 1 |
| Rektorová, I | 1 |
| Mecír, P | 1 |
| Hortová, H | 1 |
| Bares, M | 1 |
| Hejduková, B | 1 |
| Rektor, I | 1 |
| Eisdorfer, C | 1 |
| Gautier, JC | 1 |
| Durand, JP | 1 |
| Gonce, M | 1 |
| Barbeau, A | 1 |
| Lenman, JA | 1 |
| Turnbull, MJ | 1 |
| Reid, A | 1 |
| Fleming, AM | 1 |
| Miras Portugal, MT | 1 |
| Aunis, D | 1 |
| Mandel, P | 1 |
| Warter, JM | 1 |
| Coquillat, G | 1 |
| Collard, M | 1 |
| Rohmer, F | 1 |
| Feigenson, JS | 1 |
| Sweet, RD | 1 |
| McDowell, FH | 1 |
| Klawans, HL | 3 |
| Goetz, C | 1 |
| Bergen, D | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Celedová, L | 1 |
| Krsiak, M | 1 |
| Janku, I | 1 |
| Riklan, M | 1 |
| Reynolds, CM | 1 |
| Stellar, S | 1 |
| Shannon, KM | 1 |
| Goetz, CG | 1 |
| Carroll, VS | 1 |
| Tanner, CM | 1 |
| Parkes, JD | 2 |
| Baxter, RC | 2 |
| Curzon, G | 1 |
| Knill-Jones, RP | 1 |
| Knott, PJ | 1 |
| Marsden, CD | 2 |
| Tattersall, R | 1 |
| Vollum, D | 1 |
| Kamianov, IM | 1 |
| Kupisk, AG | 1 |
| Katsen, IZ | 1 |
| Merrick, EM | 1 |
| Schmitt, PP | 1 |
| Parkes, D | 1 |
| Swash, M | 1 |
| Roberts, AH | 1 |
| Zakko, H | 1 |
| Heathfield, KW | 1 |
| Klawans, H | 1 |
| Ilahi, MM | 1 |
| Shenker, D | 1 |
| Bird, MT | 1 |
| Paulson, GW | 1 |
| Pearce, J | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Lance, JW | 1 |
| Andrews, C | 1 |
| Calne, DB | 1 |
| Reid, JL | 1 |
| Topel, JL | 1 |
| Janowsky, DS | 1 |
| el-Yousef, MK | 2 |
| Davis, JM | 2 |
| Sekerke, HJ | 2 |
| Morris, DR | 1 |
| Decker, B | 1 |
| Ngai, SH | 1 |
| Ferrari, P | 1 |
| Robotti, E | 1 |
| Nardini, M | 2 |
| Rinne, UK | 1 |
| Bak, IJ | 1 |
| Hassler, R | 1 |
| Kim, JS | 1 |
| Kataoka, K | 1 |
| Reveno, WS | 1 |
| Bauer, RB | 1 |
| Rosenbaum, H | 1 |
| Dencker, SJ | 1 |
| Lindberg, D | 1 |
| Malm, U | 1 |
| Jan, JE | 1 |
| Wilson, RA | 1 |
| Herishanu, Y | 1 |
| Noah, Z | 1 |
| Dooling, EC | 1 |
| Schoene, WC | 1 |
| Richardson, EP | 1 |
| Rees, JE | 1 |
| Mann, DC | 1 |
| Pearce, LA | 1 |
| Waterbury, LD | 1 |
| Appleton, DB | 1 |
| Eadie, MJ | 1 |
| Sutherland, JM | 1 |
| Giuffrè, R | 1 |
| Gambacorta, D | 1 |
| Merren, MD | 1 |
| Critchley, E | 2 |
| Crane, GE | 1 |
| Rovetta, P | 1 |
| Ferro-Milone, F | 1 |
| Parisen-Toldin, P | 1 |
| Fanali, A | 1 |
| Sorgonà, F | 1 |
| Vergnano, M | 1 |
| Fieschi, G | 1 |
| Borromei, A | 1 |
| Lorizio, A | 1 |
| Ecari, U | 1 |
| Birkmayer, W | 1 |
| Hartmann-von Monakow, K | 1 |
| Vale, S | 1 |
| Espejel, MA | 1 |
| Decker, BL | 1 |
| Jonowsky, DS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia[NCT00950196] | Phase 4 | 30 participants (Anticipated) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for amantadine and Movement Disorders
| Article | Year |
|---|---|
[Treatment of tardive syndromes].
Topics: Amantadine; Antipsychotic Agents; Botulinum Toxins; Central Nervous System Agents; Cholinergic Antag | 2014 |
Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; alpha-Tocopherol; Amantadine; Anticonvuls | 2015 |
[The current treatment of Parkinson's disease].
Topics: Amantadine; Antidepressive Agents, Tricyclic; Dihydroxyphenylalanine; Drug Combinations; Histamine A | 1976 |
Amantadine.
Topics: Acetylcholine; Amantadine; Animals; Antiviral Agents; Basal Ganglia Diseases; Behavior, Animal; Cate | 1974 |
Theoretical implications of the use of L-dopa in parkinsonism. A review.
Topics: Acetylcholine; Amantadine; Animals; Cats; Dihydroxyphenylalanine; Dopamine; Female; Haplorhini; Huma | 1970 |
Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
Topics: Amantadine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia Diseases; Brain Che | 1971 |
Antiparkinsonian drugs: pharmacological and therapeutic aspects.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Amantadine; Amphetamine; Antiparkinson Agents; Apomorphi | 1972 |
Parkinsonism, levodopa, and anesthesia.
Topics: Amantadine; Anesthesia; Animals; Apomorphine; Benperidol; Blood-Brain Barrier; Brain; Cardiovascular | 1972 |
Recent advances in the treatment of Parkinsonism with drugs.
Topics: Amantadine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Arrhythmias, Cardiac; Blood-Brain | 1972 |
12 trials available for amantadine and Movement Disorders
| Article | Year |
|---|---|
[Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexole].
Topics: Aged; Amantadine; Benzothiazoles; Depressive Disorder, Major; Dopamine Agonists; Drug Therapy, Combi | 2008 |
Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate.
Topics: Adolescent; Amantadine; Antiparkinson Agents; Ataxia Telangiectasia; Child; Child, Preschool; Disabi | 2013 |
[Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study].
Topics: Administration, Oral; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Male; Memantine; M | 1984 |
Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders.
Topics: Amantadine; Biperiden; Double-Blind Method; Female; Humans; Male; Movement Disorders; Schizophrenia; | 1996 |
Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, | 2000 |
[Treatment of parkinsonian syndromes by bromocriptin].
Topics: Aged; Amantadine; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Human | 1977 |
A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).
Topics: Adult; Amantadine; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Female; Humans; Ma | 1973 |
Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism.
Topics: Amantadine; Clinical Trials as Topic; Humans; Movement Disorders; Parkinson Disease; Placebos | 1972 |
[Experimental design of a pilot study on amantadine in the extrapyramidal syndrome induced by neuroleptic drugs].
Topics: Amantadine; Analysis of Variance; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studi | 1972 |
Amantadine for Parkinson's disease.
Topics: Aged; Amantadine; Amines; Brain; Clinical Trials as Topic; Dihydroxyphenylalanine; Disability Evalua | 1971 |
The continued use of amantadine hydrochloride in parkinsonism.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Hydrochloric A | 1971 |
Amantadine for dyskinesia tarda.
Topics: Aged; Amantadine; Female; Humans; Middle Aged; Movement Disorders; Phenothiazines; Placebos | 1971 |
47 other studies available for amantadine and Movement Disorders
| Article | Year |
|---|---|
Reversible corneal edema associated with amantadine use: an unrecognized problem.
Topics: Aged; Amantadine; Antiparkinson Agents; Corneal Edema; Female; Humans; Movement Disorders | 2008 |
Medical treatment of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cognition Disorders; Corp | 2009 |
Drug therapies for tardive dyskinesia: Part 1.
Topics: Amantadine; Antipsychotic Agents; Buspirone; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Move | 2011 |
Profile of multiple system atrophy in Moroccan patients attending a movement disorders outpatient clinic in Rabat university hospital.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amantadine; Disease Progression; Dopamine Agonists; Fe | 2013 |
High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combin | 2005 |
Case vignettes of movement disorders.
Topics: Adult; Amantadine; Brain Injuries; Clonazepam; Diagnosis, Differential; Dystonia; Female; Haloperido | 1983 |
[Dementia--Parkinson disease: role of antiglutamatergic drugs. Symposium: 4 April, Hamburg].
Topics: Amantadine; Antipsychotic Agents; Dementia; Humans; Levodopa; Movement Disorders; Parkinson Disease; | 1998 |
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Dextromethorphan; Dextror | 1998 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone | 1975 |
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines; | 1977 |
[Dopamine beta hydroxylase. Value and limits of its study in neurology].
Topics: Amantadine; Cold Temperature; Dopamine beta-Hydroxylase; Epilepsy; Humans; Levodopa; Movement Disord | 1976 |
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Topics: Aged; Amantadine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Methyld | 1976 |
Levodopa-induced myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Amantadine; Amphetamine; Animals; Benztropine; Dopamine Antagonists; Dose | 1975 |
Actions of dopaminergic agonists on motor function.
Topics: Amantadine; Animals; Apomorphine; Behavior; Dextroamphetamine; Disease Models, Animal; Dopamine Anta | 1975 |
Immunomodulator adamantylamide dipeptide antagonizes benzodiazepine-induced rota-rod deficit in mice.
Topics: Adjuvants, Immunologic; Amantadine; Animals; Benzodiazepines; Dipeptides; Female; Mice; Movement Dis | 1989 |
Correlates of memory in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; | 1989 |
Amantadine and motor fluctuations in chronic Parkinson's disease.
Topics: Adult; Aged; Amantadine; Chronic Disease; Female; Humans; Male; Middle Aged; Movement Disorders; Par | 1987 |
Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.
Topics: Aged; Amantadine; Blood Vessels; Dihydroxyphenylalanine; Edema; Female; Gastrointestinal Diseases; H | 1971 |
[Experience with the use of midantan for treatment and prevention of the neuroleptic syndrome].
Topics: Adult; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Catatonia; Chlorpromazine; Facial Mus | 1973 |
Treatment of involuntary movement disorders with tetrabenazine.
Topics: Adolescent; Adult; Aged; Amantadine; Child; Depression; Dystonia Musculorum Deformans; Evaluation St | 1972 |
The rigid form of Huntington's chorea.
Topics: Adult; Age Factors; Amantadine; Dihydroxyphenylalanine; Female; Humans; Huntington Disease; Movement | 1971 |
Mechanism of action of amantadine.
Topics: Aged; Amantadine; Dopamine; Female; Humans; Movement Disorders; Parkinson Disease; Synaptic Transmis | 1971 |
Dysaesthesia-dyskinesia: a syndrome of painful legs and moving toes.
Topics: Aged; Amantadine; Amitriptyline; Chlorpromazine; Dihydroxyphenylalanine; Female; Humans; Leg; Moveme | 1973 |
Parkinsonism as a falling sickness.
Topics: Age Factors; Aged; Amantadine; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders | 1974 |
Amantadine actions on acetylcholine and GABA in striatum and substantia nigra of rat in relation to behavioral changes.
Topics: Acetylcholine; Acetylcholinesterase; Acetyltransferases; Alkaloids; Amantadine; Aminobutyrates; Anim | 1972 |
L-dopa for parkinsonism.
Topics: Aged; Amantadine; Depression; Dihydroxyphenylalanine; Female; Follow-Up Studies; Hallucinations; Hum | 1973 |
Amantadine in extrapyramidal syndromes induced by neuroleptic drugs.
Topics: Aged; Amantadine; Basal Ganglia Diseases; Female; Humans; Male; Middle Aged; Movement Disorders; Tra | 1973 |
Levodopa and related drugs.
Topics: Amantadine; Apomorphine; Dihydroxyphenylalanine; Humans; Hydrazines; Hypotension; Mental Disorders; | 1973 |
Unusual late neurological sequelae in galactosaemia.
Topics: Adult; Age Factors; Amantadine; Bender-Gestalt Test; Cerebellar Diseases; Diet Therapy; Erythrocytes | 1973 |
On acute encephalitic parkinsonian syndrome. Case report and review of the recent literature.
Topics: Amantadine; Child, Preschool; Delirium; Electroencephalography; Encephalitis, Arbovirus; Humans; Mal | 1973 |
Hallervorden-Spatz syndrome.
Topics: Adult; Amantadine; Autopsy; Brain; Brain Diseases; Cerebral Cortex; Deferoxamine; Electroencephalogr | 1974 |
Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Cognition Disorders; Dihydroxyphenylalanine; Drug Therapy, Combination; Edema; Eye | 1974 |
The therapeutic possibilities of L-dopa and amantadine in Parkinsonian patients who have undergone bilateral thalamotomy.
Topics: Adolescent; Adult; Aged; Amantadine; Child; Dihydroxyphenylalanine; Electroencephalography; Female; | 1971 |
Amantadine in tardive dyskinesia.
Topics: Amantadine; Humans; Movement Disorders | 1972 |
Levodopa and amantadine in the treatment of Parkinsonism.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Movement Disorders; Nau | 1972 |
Clinical manifestations of essential tremor.
Topics: Adult; Aged; Amantadine; Ataxia; Chlordiazepoxide; Dihydroxyphenylalanine; Female; Humans; Male; Mep | 1972 |
More on amantadine in tardive dyskinesia.
Topics: Amantadine; Humans; Movement Disorders; Thioridazine | 1971 |
[Long-term effects of amantadine in striatal syndromes].
Topics: Adult; Aged; Amantadine; Humans; Intracranial Arteriosclerosis; Middle Aged; Movement Disorders; Par | 1971 |
[Changes in the electroencephalogram during treatment with amantadine].
Topics: Amantadine; Brain; Chorea; Electroencephalography; Extrapyramidal Tracts; Humans; Movement Disorders | 1971 |
[Clinical study of amantadine in extrapyramidal syndromes caused by neuroleptics].
Topics: Adult; Aged; Amantadine; Extrapyramidal Tracts; Female; Humans; Male; Middle Aged; Movement Disorder | 1971 |
[On the therapeutic use of amantadine hydrochloride in non-parkinsonian hyperkinetic syndromes].
Topics: Adult; Amantadine; Athetosis; Brain Diseases; Brain Injuries; Cerebrovascular Disorders; Child; Chor | 1971 |
[Clinical and electroencephalographic observations on the action of amantadine in the dystonic-athetosic disorders of infentile cerebral paralysis].
Topics: Adolescent; Amantadine; Athetosis; Brain; Cerebral Palsy; Child; Child, Preschool; Chorea; Electroen | 1971 |
[Conservative therapy in the Parkinson syndrome].
Topics: Amantadine; Antidepressive Agents; Dihydroxyphenylalanine; Humans; Imipramine; Injections, Intraveno | 1971 |
[Treatment of the Parkinson syndrome with amantadine].
Topics: Adult; Aged; Amantadine; Arteriosclerosis; Cognition Disorders; Dihydroxyphenylalanine; Drug Interac | 1971 |
A second report on Levodopa.
Topics: Amantadine; Arrhythmias, Cardiac; Cerebrovascular Disorders; Dihydroxyphenylalanine; Humans; Hypoten | 1969 |
Amantadine hydrochloride treatment of tardive dyskinesia.
Topics: Amantadine; Female; Humans; Movement Disorders; Schizophrenia | 1971 |
Differentiation of tardive dyskinesias and drug-induced Parkinsonism.
Topics: Amantadine; Diagnosis, Differential; Dihydroxyphenylalanine; Humans; Hyperkinesis; Movement Disorder | 1971 |